Collecting biological samples from individuals with and without lung disease
Official title: Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Run by Weill Medical College of Cornell University · NCT01776398 · Data updated 2026-11-12
This study is collecting blood, urine, and airway samples from both healthy people and those with lung diseases to see how their biology differs and learn more about these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | August 29, 2012 |
| Main results expected | December 2027 |
| Study ends | December 2028 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT01776398 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older, both healthy volunteers and individuals diagnosed with lung diseases.
✕Probably not a fit
Patients who are not able to provide informed consent or are under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to gather blood, urine, and airway specimens from both healthy individuals and those diagnosed with various lung diseases, including COPD and idiopathic pulmonary fibrosis. The collected samples will be used to analyze genetic expression and other biological markers to better understand the causes and progression of lung diseases. By comparing samples from healthy controls to those with lung conditions, researchers hope to establish normal ranges for various parameters and gain insights into the pathogenesis of these diseases. The study employs techniques such as bronchoscopy to obtain airway cells for further analysis.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with lung diseases.
How similar studies have gone: Other studies have successfully utilized similar approaches to investigate lung diseases, suggesting a promising avenue for research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS (Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.): * All study subjects should be able to provide informed consent * Males or females ages 18 years and older * Must provide HIV informed consent Group 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE (As defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.): * Must provide informed consent * Males and females age 18 years and older * Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and/or (6) diseases of organs with known association with lung disease * Must provide HIV informed consent Additional Inclusion criteria for CF subjects: • All CF subjects will be homozygous for the ΔF508 mutation, with mild-moderate lung disease as defined by FEV1 ≥ 50% Group 2 - WCMC/NYPH CLINICAL PATIENTS * Must provide informed consent * Males and females, age 18 years and older * Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) diseases of organs with known association with lung disease, and (7) individuals with the blood eosinophil levels of 5% or greater. Group 3 - PCNY CLINICAL PATIENTS VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE * Must provide informed consent * Males and females, age 18 years and older * Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease Exclusion Criteria: Group 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS * Individuals not deemed in good overall health by the investigator during screening visits and/or prior to the bronchoscopy will not be accepted into the study. * Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study. * Individuals with allergies to atropine or any local anesthetic will not be accepted into the study. * Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study. * Females who are pregnant or nursing will not be accepted into the study Group 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE * Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study * Individuals deemed unable to complete the bronchoscopy due to health concerns by the investigator. * Females who are pregnant or nursing Additional Exclusion criteria for CF subjects: * Experienced a recent (≤ 8 weeks) pulmonary exacerbation of their disease Group 2 - WCMC/NYPH CLINICAL PATIENTS * Patient refuses consent Group 3 - PCNY CLINICAL PATIENTS * Patient refuses consent
Where it's running
-
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Ronald G. Crystal, M.D. — Weill Medical College of Cornell University
- Study coordinator: Niamh Savage
- Email: nis2049@med.cornell.edu
- Phone: 12127460284
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized treatment to help people with cancer quit smoking and live longer
We will test whether personalized tobacco treatment using clinical, genetic, and biomarker information helps cancer patients who smoke quit and use cessation medications more than usual care.
-
Actívatexto: Helping Latinos quit smoking and become more active
This trial tests whether Actívatexto, a text-message program combined with wearables and nicotine replacement, helps Latino adults who smoke quit and increase their physical activity.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
Technology-based motivational interviewing to help adults quit smoking
This project will try a chatbot-based motivational interviewing coach to help adult primary care patients who smoke become ready to quit and create a personalized quit plan.
-
Using an air quality monitor to encourage smoke-free homes for cancer patients
This study is testing if using an air quality monitor can help cancer patients who smoke create smoke-free homes and quit smoking.
-
Proactive tobacco treatment for household smokers through pediatric care
This study is testing a new way to help household smokers quit tobacco by using support from pediatric care to see if it can improve their chances of success.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.